Sphingosine 1 Phosphate at the Blood Brain Barrier: Can the Modulation of S1P Receptor 1 Influence the Response of Endothelial Cells and Astrocytes to Inflammatory Stimuli?
The ability of the Blood Brain Barrier (BBB) to maintain proper barrier functions, keeping an optimal environment for central nervous system (CNS) activity and regulating leukocytes' access, can be affected in CNS diseases. Endothelial cells and astrocytes are the principal BBB cellular constit...
Saved in:
Published in | PloS one Vol. 10; no. 7; p. e0133392 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Public Library of Science
21.07.2015
Public Library of Science (PLoS) |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The ability of the Blood Brain Barrier (BBB) to maintain proper barrier functions, keeping an optimal environment for central nervous system (CNS) activity and regulating leukocytes' access, can be affected in CNS diseases. Endothelial cells and astrocytes are the principal BBB cellular constituents and their interaction is essential to maintain its function. Both endothelial cells and astrocytes express the receptors for the bioactive sphingolipid S1P. Fingolimod, an immune modulatory drug whose structure is similar to S1P, has been approved for treatment in multiple sclerosis (MS): fingolimod reduces the rate of MS relapses by preventing leukocyte egress from the lymph nodes. Here, we examined the ability of S1P and fingolimod to act on the BBB, using an in vitro co-culture model that allowed us to investigate the effects of S1P on endothelial cells, astrocytes, and interactions between the two. Acting selectively on endothelial cells, S1P receptor signaling reduced cell death induced by inflammatory cytokines. When acting on astrocytes, fingolimod treatment induced the release of a factor, granulocyte macrophage colony-stimulating factor (GM-CSF) that reduced the effects of cytokines on endothelium. In an in vitro BBB model incorporating shear stress, S1P receptor modulation reduced leukocyte migration across the endothelial barrier, indicating a novel mechanism that might contribute to fingolimod efficacy in MS treatment. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Competing Interests: The study was supported by Novartis funding #CFTY7220DUSNC10T. There are no patents, products in development, or marketed products to declare. Birgit Obermeier, Anne Cotleur, and Richard M. Ransohoff are now employees of Biogen but were affiliated with the Cleveland Clinic at the time the study was performed. Simona F. Spampinato, Yukio Takeshita, Anna Love, Yasuteru Sano, and Takashi Kanda have no conflicts to declare. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials. Conceived and designed the experiments: SFS BO RMR. Performed the experiments: SFS BO AC YT AL. Analyzed the data: SFS BO AC YT RMR. Contributed reagents/materials/analysis tools: YS TK. Wrote the paper: SFS BO RMR. Edited the manuscript: AC. Current address: Neuroimmunology Research, Biogen, Cambridge, Massachusetts, United States of America. Current address: Department of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Catania, Italy. Current address: Department of Neurology and Clinical Neuroscience, Yamaguchi University, Ube, Yamaguchi, Japan. |
ISSN: | 1932-6203 1932-6203 |
DOI: | 10.1371/journal.pone.0133392 |